ArticleJCI insight2024

ORAI1 inhibition as an efficient preclinical therapy for tubular aggregate myopathy and Stormorken syndrome.

Roberto Silva-Rojas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.